TuisADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
Vorige sluiting
$0,62
Dagwisseling
$0,57 - $0,63
Jaarwisseling
$0,53 - $2,05
Markkapitalisasie
158,62 m USD
Gemiddelde volume
2,43 m
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 40,90 m | 458,83% |
Bedryfskoste | 21,28 m | 31,63% |
Netto inkomste | -17,62 m | 61,37% |
Netto winsgrens | -43,07 | 93,09% |
Wins per aandeel | -0,01 | 70,15% |
EBITDA | -11,86 m | 72,88% |
Effektiewe belastingkoers | -4,95% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 186,09 m | 15,06% |
Totale bates | 317,44 m | 7,01% |
Totale aanspreeklikheid | 237,45 m | 13,88% |
Totale ekwiteit | 79,99 m | — |
Uitstaande aandele | 255,88 m | — |
Prys om te bespreek | 2,00 | — |
Opbrengs op bates | -11,48% | — |
Opbrengs op kapitaal | -24,62% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -17,62 m | 61,37% |
Kontant van bedrywe | -54,45 m | -20,58% |
Kontant van beleggings | -66,02 m | -215,20% |
Kontant van finansiering | 25,00 m | 4 094,80% |
Netto kontantverandering | -95,25 m | -840,01% |
Beskikbare kontantvloei | -41,07 m | -62,70% |
Meer oor
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Gestig
2008
Webwerf
Werknemers
449
